Relapsed Multiple Myeloma（多発性骨髄腫）：グローバル臨床試験動向（2014年上半期）...市場調査レポートについてご紹介

Table of Contents
Table of Contents2
List of Tables 4
List of Figures 5
Introduction 6
Relapsed Multiple Myeloma 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Relapsed Multiple Myeloma 25
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Relapsed Multiple Myeloma Therapeutics Clinical Trials 32
Prominent Drugs 34
Latest Clinical Trials News on Relapsed Multiple Myeloma 35
Mar 05, 2014: Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma 35
Jan 22, 2014: Global Phase 3 Trial Commenced in Asia for Ixazomib, Takeda’s Oral Proteasome Inhibitor 35
Dec 12, 2013: Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good Tolerability and encouraging Efficacy in Combination with Lenalidomide and Dexamethasone 36
Dec 09, 2013: Interim Phase IIa Results for Spiegelmer Olaptesed Pegol in CLL and MM Studies 37
Aug 20, 2013: Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients 38
Clinical Trial Profiles 39
Clinical Trial Overview of Top Companies 39
Celgene Corporation 39
Clinical Trial Overview of Celgene Corporation 39
Amgen Inc. 43
Clinical Trial Overview of Amgen Inc. 43
Johnson & Johnson 45
Clinical Trial Overview of Johnson & Johnson 45
Takeda Pharmaceutical Company Limited 47
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 47
Novartis AG 49
Clinical Trial Overview of Novartis AG 49
Merck & Co., Inc. 51
Clinical Trial Overview of Merck & Co., Inc. 51
F. Hoffmann-La Roche Ltd. 52
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 52
Bristol-Myers Squibb Company 53
Clinical Trial Overview of Bristol-Myers Squibb Company 53
Array BioPharma Inc. 54
Clinical Trial Overview of Array BioPharma Inc. 54
AbbVie Inc. 55
Clinical Trial Overview of AbbVie Inc. 55
Clinical Trial Overview of Top Institutes / Government 56
National Cancer Institute 56
Clinical Trial Overview of National Cancer Institute 56
Mayo Clinic 58
Clinical Trial Overview of Mayo Clinic 58
The University of Texas M. D. Anderson Cancer Center 60
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 60
Memorial Sloan Kettering Cancer Center 61
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 61
University of Arkansas 62
Clinical Trial Overview of University of Arkansas 62
Washington University School of Medicine 63
Clinical Trial Overview of Washington University School of Medicine 63
Beijing Chao Yang Hospital 64
Clinical Trial Overview of Beijing Chao Yang Hospital 64
Fondazione Neoplasie Sangue Onlus 65
Clinical Trial Overview of Fondazione Neoplasie Sangue Onlus 65
Massachusetts General Hospital 66
Clinical Trial Overview of Massachusetts General Hospital 66
Five Key Clinical Profiles 67
Appendix 167
Abbreviations 167
Definitions 167
Research Methodology 168
Secondary Research 168
About GlobalData 169
Contact Us 169
Disclaimer 169
Source 170